Submitted: 24 Sep 2022
Accepted: 18 Nov 2022
ePublished: 22 Nov 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2023;12(1): e10567.
doi: 10.34172/npj.2022.10567

Scopus ID: 85146774763
  Abstract View: 5285
  PDF Download: 1661


Keep the corners; adriamycin nephropathy

Mahnaz Momenzadeh 1,2* ORCID logo

1 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan
2 Nickan Research Institute, Isfahan, Iran
*Corresponding Author: Corresponding author: Mahnaz Momenzadeh, Email: Mahnazmomenzadehf@gmail.com, , Email: Mahnaz.momenzadeh@pharm.mui.ac.ir

Implication for health policy/practice/research/medical education:

Adriamycin is an anticancer agent with broad-spectrum efficacy against tumors. However, chemotherapy-induced renal toxicity constraints clinical efficacy of cancer treatment. The nephropathy of adriamycin is detected by podocyte damage and foot process effacement, which followed by glomerulosclerosis and inflammation in the tubulointerstitial area and fibrosis. Keywords: Adriamycin, Focal segment glomerulosclerosis, Podocyte, Cardiotoxicity, Adriamycin nephropathy, Cancer

Please cite this paper as: Momenzadeh M. Keep the corners; adriamycin nephropathy. J Nephropharmacol. 2023;12(1):e10567. DOI: 10.34172/npj.2022.10567.

First Name
Last Name
Email Address
Security code

Abstract View: 5286

Your browser does not support the canvas element.

PDF Download: 1661

Your browser does not support the canvas element.